Lyra Therapeutics Inc (NASDAQ: LYRA) kicked off on Monday, down -45.31% from the previous trading day, before settling in for the closing price of $3.77. Over the past 52 weeks, LYRA has traded in a range of $2.84-$37.50.
Over the past five-year period, the drop rate of yearbook sales for the company of the Healthcare sector was -2.22%. While this was happening, its average annual earnings per share was recorded 91.08%. With a float of $1.63 million, this company’s outstanding shares have now reached $1.64 million.
Lyra Therapeutics Inc (LYRA) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Lyra Therapeutics Inc is 7.90%, while institutional ownership is 12.35%. The most recent insider transaction that took place on Jan 06 ’26, was worth 2,587. In this transaction Chief Financial Officer of this company sold 769 shares at a rate of $3.36, taking the stock ownership to the 518,547 shares. Before that another transaction happened on Jan 06 ’26, when Company’s President & CEO sold 1,702 for $3.36, making the entire transaction worth $5,726. This insider now owns 1,096,733 shares in total.
Lyra Therapeutics Inc (LYRA) Earnings and Forecasts
In the latest quarterly report, which was put into the public domain on 12/31/2024, the organization reported -7.09 earnings per share (EPS), lower than consensus estimate (set at -6.5) by -0.59. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.36 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 91.08% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 53.77% during the next five years compared to -2.22% drop over the previous five years of trading.
Lyra Therapeutics Inc (NASDAQ: LYRA) Trading Performance Indicators
Take a look at Lyra Therapeutics Inc’s (LYRA) current performance indicators. Last quarter, stock had a quick ratio of 2.43. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.10.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -23.78, a number that is poised to hit -1.92 in the next quarter and is forecasted to reach -3.62 in one year’s time.
